- Home
- SNDL vs BCYC Comparison
SNDL vs BCYC Comparison
Compare SNDL & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNDL | BCYC |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.6M | 476.6M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SNDL | BCYC |
|---|---|---|
| Price | $1.60 | $7.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $5.00 | ★ $18.73 |
| AVG Volume (30 Days) | ★ 1.9M | 240.6K |
| Earning Date | 03-17-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $683,170,243.00 | $28,339,000.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $1.15 | $6.03 |
| 52 Week High | $2.89 | $13.63 |
Technical Indicators
Market Signals| Indicator | SNDL | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 54.96 |
| Support Level | $1.45 | $6.85 |
| Resistance Level | $1.67 | $7.34 |
| Average True Range (ATR) | 0.07 | 0.32 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 60.00 | 72.18 |
Price Performance
Historical ComparisonAbout SNDL SNDL Inc.
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.